KOBV Portal

1

Online Resource

5th Japanese Association of Hepato-Biliary-Pancreatic Surgery : October 14?15, 1993, Arcadia Ichigaya, Tokyo, Japan President: Fujio Hanyu

Miyazaki, Kohji ; Tsutsumi, Nobuo ; Kitahara, Kenji ; [et al.]

Springer Science and Business Media LLC ; 1993

In: Journal of Hepato-Biliary-Pancreatic Surgery Vol. 1, No. 1 ( 1993-2), p. 42-104

add to watchlist on the watchlist

Details

In: Journal of Hepato-Biliary-Pancreatic Surgery, Springer Science and Business Media LLC, Vol. 1, No. 1 ( 1993-2), p. 42-104

Type of Medium: Online Resource

ISSN: 0944-1166 , 1436-0691

URL: Article

DOI: 10.1007/BF01235934

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 1993

detail.hit.zdb_id: 2536390-6

detail.hit.zdb_id: 1473162-9

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

2

Online Resource

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial

Tanaka, Atsushi ; Sata, Masataka ; Okada, Yosuke ; [et al.]

Oxford University Press (OUP) ; 2023

In: European Heart Journal - Cardiovascular Pharmacotherapy Vol. 9, No. 2 ( 2023-02-02), p. 165-172

add to watchlist on the watchlist

Details

In: European Heart Journal - Cardiovascular Pharmacotherapy, Oxford University Press (OUP), Vol. 9, No. 2 ( 2023-02-02), p. 165-172

Abstract: To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients. Methods and results In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0–10.0% (42–86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, and 464 patients (median age 68 years, female 31.7%, median type 2 diabetes duration 8 years, median HbA1c 7.3%) were included in the analyses. For the primary endpoint, the changes in the mean CCA-IMT from baseline to 24 months were 0.0013 [95% confidence interval (CI), −0.0155–0.0182] mm and 0.0015 (95% CI, −0.0155–0.0184) mm in the ipragliflozin and control groups, respectively, with an estimated group difference (ipragliflozin-control) of −0.0001 mm (95% CI, −0.0191–0.0189; P = 0.989). A group difference in HbA1c change at 24 months was also non-significant between the treatment groups [−0.1% (95% CI, −0.2–0.1); P = 0.359] . Conclusion Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes.

Type of Medium: Online Resource

ISSN: 2055-6837 , 2055-6845

URL: Article

DOI: 10.1093/ehjcvp/pvac059

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2023

detail.hit.zdb_id: 2808613-2

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

3

Online Resource

A Comparative Study Between Cefodizime (CDZM) and Cefotaxime (CTX) in Respiratory Tract Infections

TAKEBE, Kazuo ; IMAMURA, Kenichi ; MASUDA, Mitsuo ; [et al.]

The Japanese Association for Infectious Diseases ; 1989

In: Journal of the Japanese Association for Infectious Diseases Vol. 63, No. 4 ( 1989), p. 318-351

add to watchlist on the watchlist

Details

In: Journal of the Japanese Association for Infectious Diseases, The Japanese Association for Infectious Diseases, Vol. 63, No. 4 ( 1989), p. 318-351

Type of Medium: Online Resource

ISSN: 1884-569X , 0387-5911

Uniform Title: 呼吸器感染症に対するCefodizime (CDZM) とCefotaxime (CTX) の薬効比較試験

URL: Article

DOI: 10.11150/kansenshogakuzasshi1970.63.318

Language: English , Japanese

Publisher: The Japanese Association for Infectious Diseases

Publication Date: 1989

detail.hit.zdb_id: 2622004-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

4

Online Resource

Comparison of laminoplasty and posterior fusion surgery for cervical ossification of posterior longitudinal ligament

Nakashima, Hiroaki ; Imagama, Shiro ; Yoshii, Toshitaka ; [et al.]

Springer Science and Business Media LLC ; 2022

In: Scientific Reports Vol. 12, No. 1 ( 2022-01-14)

add to watchlist on the watchlist

Details

In: Scientific Reports, Springer Science and Business Media LLC, Vol. 12, No. 1 ( 2022-01-14)

Abstract: This prospective multicenter study, established by the Japanese Ministry of Health, Labour and Welfare and involving 27 institutions, aimed to compare postoperative outcomes between laminoplasty (LM) and posterior fusion (PF) for cervical ossification of the posterior longitudinal ligament (OPLL), in order to address the controversy surrounding the role of instrumented fusion in cases of posterior surgical decompression for OPLL. 478 patients were considered for participation in the study; from among them, 189 (137 and 52 patients with LM and PF, respectively) were included and evaluated using the Japanese Orthopaedic Association (JOA) scores, the JOA Cervical Myelopathy Evaluation Questionnaire (JOACMEQ), and radiographical measurements. Basic demographic and radiographical data were reviewed, and the propensity to choose a surgical procedure was calculated. Preoperatively, there were no significant differences among the participants in terms of patient backgrounds, radiographical measurements (K-line or cervical alignment on X-ray, OPLL occupation ratio on computed tomography, increased signal intensity change on magnetic resonance imaging), or clinical status (JOA score and JOACMEQ) after adjustments. The overall risk of perioperative complications was found to be lower with LM (odds ratio [OR] 0.40, p = 0.006), and the rate of C5 palsy occurrence was significantly lower with LM (OR 0.11, p = 0.0002) than with PF. The range of motion (20.91° ± 1.05° and 9.38° ± 1.24°, p 〈 0.0001) in patients who had PF was significantly smaller than in those who had LM. However, multivariable logistic regression analysis showed no significant difference among the participants in JOA score, JOA recovery rate, or JOACMEQ improvement at two years. In contrast, OPLL progression was greater in the LM group than in the PF group (OR 2.73, p = 0.0002). Both LM and PF for cervical myelopathy due to OPLL had resulted in comparable postoperative outcomes at 2 years after surgery.

Type of Medium: Online Resource

ISSN: 2045-2322

URL: Article

DOI: 10.1038/s41598-021-04727-1

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2022

detail.hit.zdb_id: 2615211-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

5

Online Resource

Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial

Kojima, Sunao ; Uchiyama, Kazuaki ; Yokota, Naoto ; [et al.]

Oxford University Press (OUP) ; 2022

In: Rheumatology Vol. 61, No. 6 ( 2022-05-30), p. 2346-2359

add to watchlist on the watchlist

Details

In: Rheumatology, Oxford University Press (OUP), Vol. 61, No. 6 ( 2022-05-30), p. 2346-2359

Abstract: Hyperuricaemia is recognized as an independent risk marker for cardiovascular and renal diseases. However, uric acid is a powerful free-radical scavenger, and the optimal level of serum uric acid (SUA) determining outcomes is unknown. This study explored whether interventional treatments for excessive SUA reduction were harmful and what constituted the optimal lowering of SUA levels for the prevention of events in patients with asymptomatic hyperuricaemia. Methods This was a post hoc analysis of a randomized trial (Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy [FREED]) in which 1070 older patients with asymptomatic hyperuricaemia were enrolled and allocated to febuxostat (n = 537) or non-febuxostat treatment group (n = 533). We assessed the relationship between the endpoint (withdrawal or study completion) SUA levels and clinical outcomes. Primary endpoint was defined as a composite of all-cause mortality, cerebral and cardiorenovascular events. Results In the febuxostat group, patients achieving SUA levels ≤4 mg/dl (hazard ratio: 2.01 [95% CI: 1.05, 3.87]), & gt;4 to ≤5 mg/dl (2.12 [1.07, 4.20], & gt;6 to ≤7 mg/dl (2.42 [1.05, 5.60]), and & gt;7 mg/dl (4.73 [2.13, 10.5]) had significantly higher risks for a primary composite event than those achieving SUA levels & gt;5 to ≤6 mg/dl (P = 0.003 [log-rank test]). This J-shaped relationship applied to patients with renal impairment (P = 0.007 [Gray’s test] ) and was not significant in the non-febuxostat treatment group (P = 0.212 [log-rank test]). Conclusion Optimal SUA level by febuxostat treatment is 5–6 mg/dl for reducing all-cause mortality, cerebral, cardiovascular and renal events. Excessive SUA reduction may be harmful in older hyperuricaemic populations. Trial Registration ClinicalTrial.gov, https://clinicaltrials.gov, NCT01984749

Type of Medium: Online Resource

ISSN: 1462-0324 , 1462-0332

URL: Article

DOI: 10.1093/rheumatology/keab739

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2022

detail.hit.zdb_id: 1474143-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

6

Online Resource

Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients

Soejima, Hirofumi ; Ogawa, Hisao ; Morimoto, Takeshi ; [et al.]

Springer Science and Business Media LLC ; 2023

In: Heart and Vessels Vol. 38, No. 11 ( 2023-11), p. 1371-1379

add to watchlist on the watchlist

Details

In: Heart and Vessels, Springer Science and Business Media LLC, Vol. 38, No. 11 ( 2023-11), p. 1371-1379

Type of Medium: Online Resource

ISSN: 0910-8327 , 1615-2573

URL: Article

DOI: 10.1007/s00380-023-02291-4

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2023

detail.hit.zdb_id: 1481441-9

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

7

Online Resource

Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial

Matsumoto, Chisa ; Ogawa, Hisao ; Saito, Yoshihiko ; [et al.]

American Diabetes Association ; 2020

In: Diabetes Care Vol. 43, No. 2 ( 2020-02-01), p. 314-320

add to watchlist on the watchlist

Details

In: Diabetes Care, American Diabetes Association, Vol. 43, No. 2 ( 2020-02-01), p. 314-320

Abstract: To evaluate and compare the efficacy of long-term use of low-dose aspirin for the prevention of dementia in men and women. RESEARCH DESIGN AND METHODS This study is a follow-up cohort study of the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial, which was a randomized, open-label, standard care–controlled trial examining the effects of low-dose aspirin on cardiovascular events. We followed up 2,536 Japanese patients with type 2 diabetes (T2D) enrolled in the JPAD trial from 2002 to 2017. The primary outcome of this post hoc analysis was the incidence of dementia, which was defined by the prescription of antidementia drugs or admission due to dementia. RESULTS Among the originally enrolled patients, 2,121 (84%) retained their original allocation. During a median follow-up of 11.4 years, 128 patients developed dementia. The overall effect of low-dose aspirin on the prevention of dementia adjusted for age, sex, and other established risk factors was not significant (hazard ratio [HR] 0.82, 95% CI 0.58–1.16). However, a significant reduction was seen in the risk of dementia in women (HR 0.58, 95% CI 0.36–0.95), but not in men (HR 1.27, 95% CI 0.75–2.13) (Pinteraction = 0.03). CONCLUSIONS Long-term use of low-dose aspirin may reduce the risk for dementia in women with T2D.

Type of Medium: Online Resource

ISSN: 0149-5992 , 1935-5548

URL: Article

DOI: 10.2337/dc19-1188

Language: English

Publisher: American Diabetes Association

Publication Date: 2020

detail.hit.zdb_id: 1490520-6

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

8

Online Resource

Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial

Okada, Sadanori ; Morimoto, Takeshi ; Ogawa, Hisao ; [et al.]

American Diabetes Association ; 2018

In: Diabetes Care Vol. 41, No. 8 ( 2018-08-01), p. 1757-1764

add to watchlist on the watchlist

Details

In: Diabetes Care, American Diabetes Association, Vol. 41, No. 8 ( 2018-08-01), p. 1757-1764

Abstract: This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin. After that trial ended in 2008, we followed up with the participants until 2015, with no attempt to change the previously assigned therapy. The primary end point was total cancer incidence. We investigated the effect of low-dose aspirin on cancer incidence. RESULTS During the median follow-up period of 10.7 years, a total of 318 cancers occurred. The cancer incidence was not significantly different between the aspirin and no-aspirin groups (log-rank, P = 0.4; hazard ratio [HR], 0.92; 95% CI, 0.73–1.14; P = 0.4). In subgroup analyses, aspirin did not affect cancer incidence in men, women, or participants aged ≥65 years. However, it decreased cancer incidence in participants aged & lt;65 years (log-rank, P = 0.05; HR, 0.67; 95% CI, 0.44–0.99; P = 0.048). After adjusting for sex, hemoglobin A1c, smoking status, and administration of metformin and statins, aspirin significantly reduced cancer incidence in participants aged & lt;65 years (adjusted HR, 0.66; 95% CI, 0.43–0.99; P = 0.04). CONCLUSIONS Low-dose aspirin did not reduce cancer incidence in Japanese patients with type 2 diabetes.

Type of Medium: Online Resource

ISSN: 0149-5992 , 1935-5548

URL: Article

DOI: 10.2337/dc18-0368

Language: English

Publisher: American Diabetes Association

Publication Date: 2018

detail.hit.zdb_id: 1490520-6

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

9

Online Resource

Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation

Kanaoka, Koshiro ; Onoue, Kenji ; Terasaki, Satoshi ; [et al.]

Ovid Technologies (Wolters Kluwer Health) ; 2022

In: Circulation Vol. 146, No. 19 ( 2022-11-08), p. 1425-1433

add to watchlist on the watchlist

Details

In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 146, No. 19 ( 2022-11-08), p. 1425-1433

Abstract: Fulminant myocarditis presentation (FMP) is a rare and severe presentation of myocarditis. The natural history of FMP and its clinical features associated with poor outcomes are incompletely understood because there is a lack of generalizable evidence. Methods: This multicenter retrospective cohort study included patients hospitalized with histologically proven myocarditis who underwent catecholamine or mechanical support from 235 cardiovascular training hospitals across Japan between April 2012 and March 2017. Clinical features and the prognostic predictors of death or heart transplantation within 90 days on the basis of clinical and pathologic findings were determined using the Kaplan-Meier method, log-rank test, and Cox regression analysis. Results: This study included 344 patients with histologically proven FMP (median age, 54 years; 40% female). The median follow-up was 600 days (interquartile range, 36 to 1599 days) and the cumulative risk of death or heart transplantation at 90 days was 29% (n=98). Results from multivariable Cox regression analysis showed that older age, nonsinus rhythm, low left ventricular wall motion ( 〈 40%) on admission, and ventricular tachycardia or fibrillation on admission day were associated with worse 90-day survival. Severe histologic damage (damaged cardiomyocytes comprising ≥50% of the total cardiomyocytes) was associated with a worse 90-day prognosis in patients with lymphocytic myocarditis. Conclusions: The results from analyses of data from this multicenter registry demonstrated that patients with FMP are at a higher risk of death or heart transplantation in real-world settings. These observations inform which clinical and pathologic findings may be useful for prognostication in FMP. Registration: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000039763.

Type of Medium: Online Resource

ISSN: 0009-7322 , 1524-4539

URL: Article

DOI: 10.1161/CIRCULATIONAHA.121.058869

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 2022

detail.hit.zdb_id: 1466401-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

10

Online Resource

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study

Kusunose, Kenya ; Yoshida, Hisako ; Tanaka, Atsushi ; [et al.]

Springer Science and Business Media LLC ; 2022

In: Hypertension Research Vol. 45, No. 1 ( 2022-01), p. 106-115

add to watchlist on the watchlist

Details

In: Hypertension Research, Springer Science and Business Media LLC, Vol. 45, No. 1 ( 2022-01), p. 106-115

Abstract: Hyperuricemia is related to an increased risk of cardiovascular events from a meta-analysis and antihyperuricemia agents may influence to cardiac function. We evaluated the effect of febuxostat on echocardiographic parameters of diastolic function in patients with asymptomatic hyperuricemia as a prespecified endpoint in the subanalysis of the PRIZE study. Patients in the PRIZE study were assigned randomly to either add-on febuxostat treatment group or control group with only appropriate lifestyle modification. Of the 514 patients in the overall study, 65 patients (31 in the febuxostat group and 34 in the control group) who had complete follow-up echocardiographic data of the ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e′) at baseline and after 12 and 24 months were included. The primary endpoint was a comparison of the changes in the E/e′ between the two groups from baseline to 24 months. Interestingly, e′ was slightly decreased in the control group compared with in the febuxostat group (treatment p = 0.068, time, p = 0.337, treatment × Time, p = 0.217). As a result, there were significant increases in E/e′ (treatment p = 0.045, time, p = 0.177, treatment × time, p = 0.137) after 24 months in the control group compared with the febuxostat group. There was no significant difference in the serum levels of N-terminal-pro brain natriuretic peptide and high-sensitive troponin I between the two groups during the study period. In conclusions, additional febuxostat treatment in patients with asymptomatic hyperuricemia for 24 months might have a potential of preventable effects on the impaired diastolic dysfunction.

Type of Medium: Online Resource

ISSN: 0916-9636 , 1348-4214

URL: Article

DOI: 10.1038/s41440-021-00752-9

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2022

detail.hit.zdb_id: 2110941-2

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Kooperativer Bibliotheksverbund

Berlin Brandenburg